U.S. FemTech Trends And Competitive Analysis
- Published: Jul, 2024
- Report ID: GVR-MT-100191
- Format: PDF, Horizon Databook
- No. of Pages/Datapoints: 50
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Research Methodology
1.1. Research Methodology
1.2. Research Scope and Assumption
1.3. List of Data Sources
Chapter 2. U.S. FemTech Market Trend Analysis
2.1. Femtech Expansion-Stage Deal Activity
2.2. Investment Deals in Femtech
Chapter 3. Top 30 Femtech Companies Analysis
3.1. Participant’s Overview
3.2. Financial Performance
3.3. Product and Service Benchmarking
3.4. Strategy Mapping
3.5. Funding Overview
3.5.1. Investors
3.5.2. Round Type
3.5.3. Round Number
3.6. Company Profiles
3.6.1. Maven Clinic
3.6.1.1. Overview
3.6.1.2. Financial performance
3.6.1.3. Product and Service Benchmarking
3.6.1.4. Strategic initiatives
3.6.1.5. Funding Overview
3.6.1.5.1. Investors
3.6.1.5.2. Round Type
3.6.1.5.3. Round Number
3.6.2. Kindbody
3.6.2.1. Overview
3.6.2.2. Financial performance
3.6.2.3. Product and Service Benchmarking
3.6.2.4. Strategic initiatives
3.6.2.5. Funding Overview
3.6.2.5.1. Investors
3.6.2.5.2. Round Type
3.6.2.5.3. Round Number
3.6.3. Celmatix
3.6.3.1. Overview
3.6.3.2. Financial performance
3.6.3.3. Product and Service Benchmarking
3.6.3.4. Strategic initiatives
3.6.3.5. Funding Overview
3.6.3.5.1. Investors
3.6.3.5.2. Round Type
3.6.3.5.3. Round Number
3.6.4. Flo
3.6.4.1. Overview
3.6.4.2. Financial performance
3.6.4.3. Product and Service Benchmarking
3.6.4.4. Strategic initiatives
3.6.4.5. Funding Overview
3.6.4.5.1. Investors
3.6.4.5.2. Round Type
3.6.4.5.3. Round Number
3.6.5. Bloomlife
3.6.5.1. Overview
3.6.5.2. Financial performance
3.6.5.3. Product and Service Benchmarking
3.6.5.4. Strategic initiatives
3.6.5.5. Funding Overview
3.6.5.5.1. Investors
3.6.5.5.2. Round Type
3.6.5.5.3. Round Number
3.6.6. Carrot Fertility
3.6.6.1. Overview
3.6.6.2. Financial performance
3.6.6.3. Product and Service Benchmarking
3.6.6.4. Strategic initiatives
3.6.6.5. Funding Overview
3.6.6.5.1. Investors
3.6.6.5.2. Round Type
3.6.6.5.3. Round Number
3.6.7. Gennev
3.6.7.1. Overview
3.6.7.2. Financial performance
3.6.7.3. Product and Service Benchmarking
3.6.7.4. Strategic initiatives
3.6.7.5. Funding Overview
3.6.7.5.1. Investors
3.6.7.5.2. Round Type
3.6.7.5.3. Round Number
3.6.8. Elvie
3.6.8.1. Overview
3.6.8.2. Financial performance
3.6.8.3. Product and Service Benchmarking
3.6.8.4. Strategic initiatives
3.6.8.5. Funding Overview
3.6.8.5.1. Investors
3.6.8.5.2. Round Type
3.6.8.5.3. Round Number
3.6.9. Marani Health
3.6.9.1. Overview
3.6.9.2. Financial performance
3.6.9.3. Product and Service Benchmarking
3.6.9.4. Strategic initiatives
3.6.9.5. Funding Overview
3.6.9.5.1. Investors
3.6.9.5.2. Round Type
3.6.9.5.3. Round Number
3.6.10. Oula Health
3.6.10.1. Overview
3.6.10.2. Financial performance
3.6.10.3. Product and Service Benchmarking
3.6.10.4. Strategic initiatives
3.6.10.5. Funding Overview
3.6.10.5.1. Investors
3.6.10.5.2. Round Type
3.6.10.5.3. Round Number
3.6.11. Renovia
3.6.11.1. Overview
3.6.11.2. Financial performance
3.6.11.3. Product and Service Benchmarking
3.6.11.4. Strategic initiatives
3.6.11.5. Funding Overview
3.6.11.5.1. Investors
3.6.11.5.2. Round Type
3.6.11.5.3. Round Number
3.6.12. Aavia
3.6.12.1. Overview
3.6.12.2. Financial performance
3.6.12.3. Product and Service Benchmarking
3.6.12.4. Strategic initiatives
3.6.12.5. Funding Overview
3.6.12.5.1. Investors
3.6.12.5.2. Round Type
3.6.12.5.3. Round Number
3.6.13. ART Compass
3.6.13.1. Overview
3.6.13.2. Financial performance
3.6.13.3. Product and Service Benchmarking
3.6.13.4. Strategic initiatives
3.6.13.5. Funding Overview
3.6.13.5.1. Investors
3.6.13.5.2. Round Type
3.6.13.5.3. Round Number
3.6.14. Lia
3.6.14.1. Overview
3.6.14.2. Financial performance
3.6.14.3. Product and Service Benchmarking
3.6.14.4. Strategic initiatives
3.6.14.5. Funding Overview
3.6.14.5.1. Investors
3.6.14.5.2. Round Type
3.6.14.5.3. Round Number
3.6.15. MCH Ventures, Inc.
3.6.15.1. Overview
3.6.15.2. Financial performance
3.6.15.3. Product and Service Benchmarking
3.6.15.4. Strategic initiatives
3.6.15.5. Funding Overview
3.6.15.5.1. Investors
3.6.15.5.2. Round Type
3.6.15.5.3. Round Number
3.6.16. Emme
3.6.16.1. Overview
3.6.16.2. Financial performance
3.6.16.3. Product and Service Benchmarking
3.6.16.4. Strategic initiatives
3.6.16.5. Funding Overview
3.6.16.5.1. Investors
3.6.16.5.2. Round Type
3.6.16.5.3. Round Number
3.6.17. Modern Fertility
3.6.17.1. Overview
3.6.17.2. Financial performance
3.6.17.3. Product and Service Benchmarking
3.6.17.4. Strategic initiatives
3.6.17.5. Funding Overview
3.6.17.5.1. Investors
3.6.17.5.2. Round Type
3.6.17.5.3. Round Number
3.6.18. Proov
3.6.18.1. Overview
3.6.18.2. Financial performance
3.6.18.3. Product and Service Benchmarking
3.6.18.4. Strategic initiatives
3.6.18.5. Funding Overview
3.6.18.5.1. Investors
3.6.18.5.2. Round Type
3.6.18.5.3. Round Number
3.6.19. YourChoice Therapeutics
3.6.19.1. Overview
3.6.19.2. Financial performance
3.6.19.3. Product and Service Benchmarking
3.6.19.4. Strategic initiatives
3.6.19.5. Funding Overview
3.6.19.5.1. Investors
3.6.19.5.2. Round Type
3.6.19.5.3. Round Number
3.6.20. The Flex Co.
3.6.20.1. Overview
3.6.20.2. Financial performance
3.6.20.3. Product and Service Benchmarking
3.6.20.4. Strategic initiatives
3.6.20.5. Funding Overview
3.6.20.5.1. Investors
3.6.20.5.2. Round Type
3.6.20.5.3. Round Number
3.6.21. Ovia Health
3.6.21.1. Overview
3.6.21.2. Financial performance
3.6.21.3. Product and Service Benchmarking
3.6.21.4. Strategic initiatives
3.6.21.5. Funding Overview
3.6.21.5.1. Investors
3.6.21.5.2. Round Type
3.6.21.5.3. Round Number
3.6.22. Mumspring
3.6.22.1. Overview
3.6.22.2. Financial performance
3.6.22.3. Product and Service Benchmarking
3.6.22.4. Strategic initiatives
3.6.22.5. Funding Overview
3.6.22.5.1. Investors
3.6.22.5.2. Round Type
3.6.22.5.3. Round Number
3.6.23. FertilityIQ
3.6.23.1. Overview
3.6.23.2. Financial performance
3.6.23.3. Product and Service Benchmarking
3.6.23.4. Strategic initiatives
3.6.23.5. Funding Overview
3.6.23.5.1. Investors
3.6.23.5.2. Round Type
3.6.23.5.3. Round Number
3.6.24. iSono Health
3.6.24.1. Overview
3.6.24.2. Financial performance
3.6.24.3. Product and Service Benchmarking
3.6.24.4. Strategic initiatives
3.6.24.5. Funding Overview
3.6.24.5.1. Investors
3.6.24.5.2. Round Type
3.6.24.5.3. Round Number
3.6.25. Ava Science, Inc. (FemTec Health, Inc..)
3.6.25.1. Overview
3.6.25.2. Financial performance
3.6.25.3. Product and Service Benchmarking
3.6.25.4. Strategic initiatives
3.6.25.5. Funding Overview
3.6.25.5.1. Investors
3.6.25.5.2. Round Type
3.6.25.5.3. Round Number
3.6.26. Glow
3.6.26.1. Overview
3.6.26.2. Financial performance
3.6.26.3. Product and Service Benchmarking
3.6.26.4. Strategic initiatives
3.6.26.5. Funding Overview
3.6.26.5.1. Investors
3.6.26.5.2. Round Type
3.6.26.5.3. Round Number
3.6.27. Lola
3.6.27.1. Overview
3.6.27.2. Financial performance
3.6.27.3. Product and Service Benchmarking
3.6.27.4. Strategic initiatives
3.6.27.5. Funding Overview
3.6.27.5.1. Investors
3.6.27.5.2. Round Type
3.6.27.5.3. Round Number
3.6.28. NaturalCycles
3.6.28.1. Overview
3.6.28.2. Financial performance
3.6.28.3. Product and Service Benchmarking
3.6.28.4. Strategic initiatives
3.6.28.5. Funding Overview
3.6.28.5.1. Investors
3.6.28.5.2. Round Type
3.6.28.5.3. Round Number
3.6.29. Clue by Biowink
3.6.29.1. Overview
3.6.29.2. Financial performance
3.6.29.3. Product and Service Benchmarking
3.6.29.4. Strategic initiatives
3.6.29.5. Funding Overview
3.6.29.5.1. Investors
3.6.29.5.2. Round Type
3.6.29.5.3. Round Number
3.6.30. Lucina Health
3.6.30.1. Overview
3.6.30.2. Financial performance
3.6.30.3. Product and Service Benchmarking
3.6.30.4. Strategic initiatives
3.6.30.5. Funding Overview
3.6.30.5.1. Investors
3.6.30.5.2. Round Type
3.6.30.5.3. Round Number
3.6.31. Expectful
3.6.31.1. Overview
3.6.31.2. Financial performance
3.6.31.3. Product and Service Benchmarking
3.6.31.4. Strategic initiatives
3.6.31.5. Funding Overview
3.6.31.5.1. Investors
3.6.31.5.2. Round Type
3.6.32. March Health
3.6.32.1. Overview
3.6.32.2. Financial performance
3.6.32.3. Product and Service Benchmarking
3.6.32.4. Strategic initiatives
3.6.32.5. Funding Overview
3.6.32.5.1. Investors
3.6.32.5.2. Round Type
3.6.33. Phexxi
3.6.33.1. Overview
3.6.33.2. Financial performance
3.6.33.3. Product and Service Benchmarking
3.6.33.4. Strategic initiatives
3.6.33.5. Funding Overview
3.6.33.5.1. Investors
3.6.33.5.2. Round Type
3.6.34. Tia
3.6.34.1. Overview
3.6.34.2. Financial performance
3.6.34.3. Product and Service Benchmarking
3.6.34.4. Strategic initiatives
3.6.34.5. Funding Overview
3.6.34.5.1. Investors
3.6.34.5.2. Round Type
3.6.35. Syantra
3.6.35.1. Overview
3.6.35.2. Financial performance
3.6.35.3. Product and Service Benchmarking
3.6.35.4. Strategic initiatives
3.6.35.5. Funding Overview
3.6.35.5.1. Investors
3.6.35.5.2. Round Type
3.6.35.5.3. Round Number
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.